Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.

@article{Bernemann2017ExpressionOA,
  title={Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.},
  author={Christof Bernemann and Thomas J Schnoeller and Manuel Luedeke and Konrad Steinestel and Martin Boegemann and Andres Jan Schrader and Julie Steinestel},
  journal={European urology},
  year={2017},
  volume={71 1},
  pages={1-3}
}
The androgen receptor splice variant AR-V7 has recently been discussed as a predictive biomarker for nonresponse to next-generation androgen deprivation therapy (ADT) in patients with castration-resistant prostate cancer. However, we recently identified one patient showing a response from abiraterone despite expression of AR-V7 in his circulating tumour cells (CTC). Therefore, we precisely assessed the response in a cohort of 21 AR-V7 positive castration-resistant prostate cancer patients who… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 38 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 12 references

Similar Papers

Loading similar papers…